Immunosuppression
Research News and Information

Sunday, November 22, 2009

Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99).

29 Nov 2009 BACKGROUND: Although hematopoietic stem cell transplantation (HSCT) is offered as a curative therapy for pediatric myelodysplastic syndrome (MDS), it may cause severe complications and mortality. Several reports have shown the efficacy of ... Read more...

Repopulation of vascularized bone allotransplants with recipient-derived cells: detection by laser capture microdissection and real-time PCR.

30 Oct 2009 Mechanisms underlying successful composite tissue transplantation must include an analysis of transplant chimerism, which is little studied, particularly in calcified tissue. We have developed a new method enabling determination of lineage of ... Read more...

Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.

29 Sep 2009 The risk of lymphoproliferative disorders (LDs) has become a major concern for clinicians managing patients with inflammatory bowel disease (IBD). Yet it is difficult to distinguish the possible responsibility of immunosuppressive therapy from the ... Read more...

Latest indexed articles for 'Immunosuppression'

These are the very latest articles for this heading:

• Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99). 29 Nov 2009
• Repopulation of vascularized bone allotransplants with recipient-derived cells: detection by laser capture microdissection and real-time PCR. 30 Oct 2009
• Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. 29 Sep 2009
• Recurrence of bile salt export pump deficiency after liver transplantation. 29 Sep 2009
• Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. 29 Sep 2009
• Spitting image: tick saliva assists the causative agent of Lyme disease in evading host skin's innate immune response. 29 Sep 2009
• Ethanol induces apoptosis in human mast cells. 18 Sep 2009
• From plasma BK viral load to allograft damage: rule of thumb for estimating the intrarenal cytopathic wear. 13 Sep 2009
• Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. 13 Sep 2009
• Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. 13 Sep 2009
• The search for infectious causes of human cancers: where and why. 13 Sep 2009
• Mesenchymal stromal cells. 30 Aug 2009
• Targets of protective tumor immunity. 30 Aug 2009
• Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. 30 Aug 2009
• Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. 30 Aug 2009
• Interleukin-1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia. 30 Aug 2009
• Dendritic cells in intestinal homeostasis and disease. 30 Aug 2009
• Methylglyoxal: possible link between hyperglycaemia and immune suppression? 22 Aug 2009
• The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. 17 Aug 2009
• Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine production. 13 Aug 2009

See a longer list of these articles.

Technical information about 'Immunosuppression'

Definition: Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.

Descriptor UI: D007165

Alternative terms: Immunosuppression; Immunosuppressions; Therapy, Anti-Rejection; Anti-Rejection Therapy; Anti Rejection Therapy; Anti-Rejection Therapies; Therapy, Antirejection; Antirejection Therapies; Antirejection Therapy;

Related Mesh Headings: Antilymphocyte Serum; Immune Tolerance; Immunocompromised Host;

Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics;

Tree Number: E02.095.520.450; E05.478.610;

History Note: 72(71)

Technical Notes: note category: "deliberate prevention or diminution of the host's immune response": do not confuse with IMMUNOSUPPRESSION (PHYSIOLOGY) see IMMUNE TOLERANCE (G4); do not use /util except by MeSH definition; OPPORTUNISTIC INFECTIONS is available if particularly discussed: see note there